Vivesto AB OASMY OTC · Healthcare · Sweden
$0.00 +0.00% +$0.00
Summary
39 / 100 · Bulios Score
What speaks for it
- It could repay all its net debt from 0.0 years of operating profit.
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
- For every 100 SEK of bills due within a year it has 38 SEK of short-term assets.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
It is shrinkingRevenue (SEK)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 676.00%
You receive $0.00 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.